Biodesix, Inc. (NASDAQ:BDSX) Shares Sold by AMH Equity Ltd

AMH Equity Ltd decreased its holdings in shares of Biodesix, Inc. (NASDAQ:BDSX) by 6.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 651,868 shares of the company’s stock after selling 44,205 shares during the quarter. Biodesix comprises about 1.0% of AMH Equity Ltd’s portfolio, making the stock its 26th biggest holding. AMH Equity Ltd owned approximately 0.45% of Biodesix worth $997,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new stake in Biodesix during the 3rd quarter valued at about $10,849,000. Perkins Capital Management Inc. boosted its holdings in shares of Biodesix by 74.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after purchasing an additional 310,000 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Biodesix by 50.7% during the 3rd quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock worth $1,433,000 after purchasing an additional 270,724 shares during the last quarter. Stephens Inc. AR purchased a new stake in shares of Biodesix in the fourth quarter valued at approximately $303,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of Biodesix in the third quarter valued at approximately $262,000. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Biodesix

In other news, CEO Scott Hutton sold 83,660 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the sale, the chief executive officer now owns 701,947 shares in the company, valued at $645,791.24. This trade represents a 10.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 128,702 shares of company stock worth $118,406 in the last quarter. Company insiders own 69.20% of the company’s stock.

Biodesix Stock Performance

Shares of Biodesix stock opened at $0.83 on Thursday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. The business’s 50 day moving average price is $1.16 and its 200 day moving average price is $1.44. The company has a market cap of $120.98 million, a price-to-earnings ratio of -2.13 and a beta of 1.06. Biodesix, Inc. has a one year low of $0.75 and a one year high of $2.04.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.